NOVEMBER 2024LIFE SCIENCES REVIEW9In a relatively short amount of time, clinicians and scientists have advanced the concept of transforming one's own immune cells into potent anti-cancer agents and moved rapidly toward bringing these innovative therapies to hospitals around the worldcurative treatments, some of these products are built on allogeneic cell sources, in order to establish off-the-shelf cell therapies that are readily available to many patients. Devising a viable strategy to ensure timely and efficient manufacturing of these cell-based drugs is a critical step to ensure patients receive their treatment as quickly as possible. Despite the notable progress in therapy development, manufacturing still remains a bottleneck that delays the transition of these drugs to the clinic. Because cell-based therapies, unlike other medicines, are "living drugs" whose properties can be altered by even small manipulations and process changes, it is also important to design an appropriate manufacturing strategy to support robust and reproducible generation of the clinical product. Integration of automation into the manufacturing process can reduce costs and labor by consolidating multiple unit operations into a single platform, supporting large-scale production, and reducing errors. Given the fast-growing product pipeline, developing flexible and scalable platforms that support large-scale manufacturing of both autologous and allogeneic products is necessary to enable a viable path to commercial readiness.Moreover, defining whether manufacturing will be governed by a distributed or a centralized model will play an important role in identifying strategies that best suit each product and clinical intent. Additionally, applying tools such as automated tracking systems, chain-of-custody/chain-of-identity controls, and establishing standardized, commercially-compliant quality assurance programs are critical steps to support robust implementation. Involving regulators early on in this decision-making process can provide guidance and clarity and help to increase the speed of development, enabling innovators to bring these therapies to patients faster. Tamara J. Laskowski
< Page 8 | Page 10 >